SEARCH

SEARCH BY CITATION

References

  • 1
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893917.
  • 2
    Danish Medicines Agency. Sales of Medicinal Products Within the Different ATC Groups in the Primary Healthcare Sector. Medicinal Product Statistics 2006–2010. Denmark Copenhagen: Danish Medicines Agency, 2011; 80.
  • 3
    Sorensen HT, Mellemkjaer L, Nielsen GL, Baron JA, Olsen JH, Karagas MR. Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst 2004; 96: 70911.
  • 4
    Karagas MR, Cushing GL Jr, Greenberg ER, Mott LA, Spencer SK, Nierenberg DW. Non-melanoma skin cancers and glucocorticoid therapy. Br J Cancer 2001; 85: 6836.
  • 5
    Jensen AO, Thomsen HF, Engebjerg MC, et al. Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case-control study. Br J Cancer 2009; 100: 2005.
  • 6
    Dietrich K, Schned A, Fortuny J, et al. Glucocorticoid therapy and risk of bladder cancer. Br J Cancer 2009; 101: 131620.
  • 7
    Severi G, Baglietto L, Muller DC, et al. Asthma, asthma medications, and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2010; 19: 231824.
  • 8
    Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman and Gilman's the Pharmacological Basis of Therapeutics. New York: McGraw-Hill Medical Publishing Division, 2006; 1587612.
  • 9
    Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006; 6: 83648.
  • 10
    Fulop T, Larbi A, Kotb R, de Angelis F, Pawelec G. Aging, immunity, and cancer. Discov Med 2011; 11: 53750.
  • 11
    Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002; 96: 2343.
  • 12
    Siddiqui AA. Metabolic syndrome and its association with colorectal cancer: a review. Am J Med Sci 2011; 341: 22731.
  • 13
    Lin JH, Morikawa T, Chan AT, et al. Postmenopausal hormone therapy is associated with a reduced risk of colorectal cancer lacking CDKN1A expression. Cancer Res 2012; 72: 30208.
  • 14
    Subramanian V, Logan RF. Chemoprevention of colorectal cancer in inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2011; 25: 593606.
  • 15
    Statistics Denmark. StatBank Denmark. 2012. Available at: http://www.statistikbanken.dk/statbank5a/SelectVarVal/Define.asp?Maintable=FOLK1&PLanguage=1. Accessed September 20, 2012.
  • 16
    Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry-history, content, quality and use. Dan Med Bull 1997; 44: 5359.
  • 17
    Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health 2011; 39(Suppl.): 425.
  • 18
    Sobin LH. TNM: evolution and relation to other prognostic factors. Semin Surg Oncol 2003; 21: 37.
  • 19
    Pedersen CB. The Danish Civil Registration System. Scand J Public Health 2011; 39(Suppl.): 225.
  • 20
    Ehrenstein V, Antonsen S, Pedersen L. Existing data sources for clinical epidemiology: Aarhus University Prescription Database. Clin Epidemiol 2010; 2: 2739.
  • 21
    Jacobs JWG, Bijlsma JWJ. Glucocorticoid Therapy. In: Firestein GS, Budd RC, Harris ED, McInnes IB, Sergent JS, eds. Kelly's Textbook of Rheumatology. 8th ed. St. Louis, MO: W.B. Saunders Company, 2008; 863.
  • 22
    Sorensen GV, Cronin-Fenton DP, Sorensen HT, Ulrichsen SP, Pedersen L, Lash TL. Use of glucocorticoids and risk of breast cancer: a Danish population-based case-control study. Breast Cancer Res 2012; 14: R21.
  • 23
    Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999; 46: 2638.
  • 24
    Hosmer DW, Lemeshow S The Multinomal Logistic Regression Model. Applied Logistic Regression. 2nd ed. Hoboken NJ: John Wiley and Sons, Inc., 2000; 260.
  • 25
    Nielsen GL, Sorensen HT, Mellemkjoer L, et al. Risk of hospitalization resulting from upper gastrointestinal bleeding among patients taking corticosteroids: a register-based cohort study. Am J Med 2001; 111: 5415.
  • 26
    Parimon T, Chien JW, Bryson CL, McDonell MB, Udris EM, Au DH. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 7129.
  • 27
    Sorensen HT, Lash TL, Rothman KJ. Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies. Hepatology 2006; 44: 107582.
  • 28
    Johannesdottir SA, Maegbaek ML, Hansen JG, Lash TL, Pedersen L, Ehrenstein V. Correspondence between general practitioner reported medication use and timing of prescription dispensation. Clin Epidemiol 2012; 4: 138.
  • 29
    Mellemkjaer L, Blot WJ, Sorensen HT, et al. Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark. Br J Clin Pharmacol 2002; 53: 17381.
  • 30
    Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010; 376: 174150.